R

Resmed

Cloud-connected medical devices and software platforms

Product Manager - PLE

Full-TimeUpdated Deadline 11/5/26
No salary listed
Mid
Sydney NSW, Australia+1 moreMore locations: Singapore
In PersonThe role is based in Sydney or Singapore.
ProductProduct Management

About the job

Requirements
  • A genuine interest in user-centred design, sleep health, and medical technology.
  • Use strategic thinking and a data-informed approach to decision-making.
  • Assess competing priorities and maintain focus on meaningful outcomes.
  • Communicate clearly and work collaboratively.
Responsibilities
  • Champion patient and provider needs throughout the product lifecycle.
  • Monitor in-market product performance and identify opportunities to maintain quality and competitiveness.
  • Gather insights and help turn them into clear, prioritised actions.
  • Own a product within the mask portfolio or provide hands-on support across development and launch.
  • Partner with Manufacturing, Regulatory, Quality, Supply, Marketing, and Engineering teams.
  • Influence priorities and support the effective delivery of cross-functional projects.
  • Contribute to new product introductions and broader strategic initiatives.
  • Measure success through user satisfaction and business impact.
  • Help the team build the right products, build them well, and deliver them efficiently.
  • Think strategically about the current portfolio and make in-market adjustments to leverage its value, working with the commercial and marketing teams.
Desired Qualifications
  • Background in hardware product management.
  • Exposure to regulated medical devices.

About the company

R

Resmed

View
Website

ResMed creates cloud-connected medical devices and software platforms to treat and manage sleep apnea, COPD, and other chronic diseases. Its devices (like sleep therapy gear) collect patient data and deliver therapy, while connected software platforms enable remote monitoring, coaching, and caregiver support. The company sells medical devices and offers software subscriptions, generating revenue from product sales and ongoing service fees. Unlike some competitors, ResMed combines hardware with cloud-based analytics and a broad ecosystem that supports patients, healthcare professionals, and caregivers across more than 120 countries. Its goal is to improve patient care and quality of life while reducing hospital visits and overall healthcare costs.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1989

Get referred to Resmed

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 guidance shows 5%-7% revenue growth and 12%-14% core EPS growth.
  • MatrixCare closed September 1, 2026, freeing capital for higher-margin core businesses.
  • ResMed's connected network and Oura partnership expand diagnosis and PAP adoption funnels.

What critics are saying

  • Astral no-new-sales in fiscal 2027 removes $75 million revenue and damages trust.
  • KPMG exit and PwC onboarding increase reporting disruption risk before the next 10-Q.
  • Philips Respironics' U.S. return in 2027 can compress pricing and share quickly.

What makes Resmed unique

  • ResMed's cloud-connected AirSense platform locks in recurring resupply and adherence data.
  • Noctrix acquisition broadens ResMed beyond apnea into restless legs syndrome treatments.
  • MatrixCare sale and core-device focus sharpen execution around sleep, breathing, and home care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Holidays
  • Parental Leave
  • 401(k) Retirement Plan
  • Employee Assistance Program (EAP)

Growth & Insights and Company News

6 month growth

0%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 30th, 2026
ResMed Q1 revenue rises 7% to $1.4B, EPS up 14%, with record $1B returned to shareholders

ResMed reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% reported and 7% on a core constant currency basis. Non-GAAP earnings per share rose 14% to $2.91, and gross margin gained 50 basis points to 62.5%. The sleep apnoea device maker returned more than $1 billion to shareholders through dividends and buybacks, a record. Buybacks alone totalled $936 million. Free cash flow fell to $374 million on higher inventory and cash tax prepaids. Life support device revenue dropped 94% in the Americas and 79% in the rest of the world after a field safety action on its Astral device. ResMed took a $42 million reserve. It kept full-year guidance: revenue of $5.75 billion to $5.85 billion and non-GAAP EPS of $12 to $12.25.

Stockhead
Oct 30th, 2026
Lunch Wrap: ASX in the green but Coles and Catalyst cop a hiding.

Lunch Wrap: ASX in the green but Coles and Catalyst cop a hiding. * ASX was up this morning as retailers rebound * Coles cops an 11% beating as sales disappoint * Wall Street's AI party turns into a hangover The S&P/ASX 200 was charging 0.5% higher by lunchtime in Sydney. And after yesterday's retail massacre, bargain hunters were back rummaging through the wreckage. Overnight, Wall Street had a shocker as Google parent Alphabet crashed more than 12%, vaporising over US$500 billion after disappointing earnings. Back home this morning, the real action was in consumer discretionary, which jumped higher after four straight days of punishment. But consumer staples were having a stinker, thanks to Coles Group (ASX:COL). Coles plunged as much as 11% after warning first-half supermarket earnings would be flat, rather than growing as analysts expected. Its supermarket sales rose just 3.6%, versus Woolworths (ASX:WOW)'s 6.1%, while liquor sales fell 1.3%. Coles blamed fierce discounting, stretched shoppers and rising fuel costs. It's now rolling out more promotions to win customers back. In other large cap news... Dan Murphy's owner Endeavour Group (ASX:EDV) managed to squeeze out a 2.8% lift in quarterly sales to $3.18 billion, although even Aussies are starting to think twice before stocking the beer fridge. Over at Reece (ASX:REH), things were flowing rather nicely. The plumbing giant shot up 7% after quarterly sales rose 4.3% to $2.51 billion. Turns out there's still plenty of money to be made selling taps and toilets, even when the rest of the economy looks a little constipated. Sleep machine maker ResMed (ASX:RMD) was also having a good one, rising 3% after net income climbed 12% to US$418 million. Demand for its sleep apnoea gear remains strong, while bigger share buybacks gave investors another reason to rest easy. Meanwhile, Car Group (ASX:CAR) was busy telling investors that AI wasn't about to steal its lunch money. The carsales owner reckons its 52 million-plus monthly users, massive dealer network and two decades of pricing data give it a pretty decent moat. Over in energy, Origin Energy (ASX:ORG) was laughing all the way to the bank after quarterly LNG revenue jumped 32% to $2.6 billion. It wasn't pumping out heaps more gas, mind you. It was simply getting paid more for what it sold. Sometimes the easiest way to make more money is to charge more. QatarEnergy, from one of the world's biggest gas-exporting nations, has signed up to buy as much as three million tonnes of LNG a year from Woodside's Louisiana project for 20 years, starting in 2029. Yep, Qatar buying American gas. That's a little like a bakery shop popping over next door to buy a loaf of bread. Over in mining, Rio Tinto (ASX:RIO) had a headache after seismic activity forced it to suspend underground operations at its giant Oyu Tolgoi copper mine in Mongolia. Three workers were injured, while transport delays at the Chinese border added to the drama. Not ideal when copper is supposed to be one of Rio's big growth engines. Its shares crashed 22% after quarterly gold production tumbled 30% to 22,200 ounces, costs went through the roof and FY27 production guidance was chopped to 90,000-105,000 ounces. To make matters worse, first production from two new mines has been pushed into FY28. Catalyst still has $371 million sitting in cash and bullion, which is a pretty decent cushion. And finally... Emerald Resources (ASX:EMR) also had a quarter it probably wouldn't be framing for the meeting room wall. Gold production fell 25% and costs jumped 48% as it processed lower-grade ore. Still, Emerald stuck with its FY27 guidance and had $540.9 million in liquid assets. ASX leaders. Today's best performing stocks (including small caps) intraday: | Security | Description | Last | % | Volume | MktCap | | AGN | Argenica | 0.115 | 10% | 173,128 | $13,487,955 | | ATC | Altech Batt Ltd | 0.002 | 50% | 2,087,588 | $2,669,056 | | BOA | BOA Resources Ltd | 0.110 | 10% | 347,603 | $51,271,350 | | BOC | Bougainville Copper | 0.170 | 13% | 118,139 | $60,159,375 | | BTN | Butn Limited | 0.013 | 86% | 42,000 | $2,672,019 | | CUP | Count Limited | 1.635 | 22% | 704,878 | $290,124,223 | | CYC | Cyclopharm Limited | 0.435 | 13% | 66,686 | $48,407,646 | | DKM | Duketon Mining | 0.100 | 11% | 1,847 | $11,227,514 | | EXT | Excite Technology | 0.006 | 10% | 55,889 | $13,815,824 | | FRB | Firebird Metals | 0.145 | 12% | 148,000 | $23,706,982 | | IOV | Ion Video Ltd | 0.610 | 23% | 109,380 | $70,028,820 | | ITM | Itech Minerals Ltd | 0.037 | 12% | 148,024 | $7,883,218 | | KTA | Krakatoa Resources | 0.005 | 11% | 544,780 | $9,055,175 | | LNQ | Linqmineralslimited | 0.545 | 18% | 1,445,641 | $42,473,900 | | LVE | Love Group Global | 0.120 | 14% | 209,860 | $4,256,088 | | MCA | Murray Cod Aust Ltd | 0.150 | 15% | 175,929 | $32,223,177 | | ODA | Orcoda Limited | 0.059 | 9% | 106,461 | $10,125,767 | | PET | Phoslock Env Tec Ltd | 0.009 | 13% | 67,111 | $4,995,124 | | RAD | Radiopharm | 0.005 | 13% | 54,821 | $18,843,531 | | SRJ | SRJ Technologies | 0.005 | 25% | 5,747,500 | $6,892,874 | | SUH | Southern Hem Min | 0.034 | 17% | 1,890,882 | $21,350,961 | | T3D | 333D Limited | 0.035 | 40% | 50,000 | $5,284,887 | | TRI | Trivarx Ltd | 0.009 | 13% | 4,790,097 | $9,229,548 | | WMG | Western Mines | 0.155 | 11% | 30,800 | $18,252,013 | | WRK | Wrkr Ltd | 0.088 | 11% | 560,034 | $171,539,483 | Count Limited (ASX:CUP) has snapped up a 30% stake in Brisbane accounting and financial advice firm Apiary, which generated $3.5 million in FY26 revenue. It's also kicked off FY27 with a bang, lifting quarterly revenue 23.2% to $52.1 million and underlying earnings 66.6% to $12.7 million, while funds under management hit a record $6.7 billion. Butn (ASX:BTN) has extended its invoice financing partnership with MYOB until November 2027, keeping cashflow funding available to small businesses through the accounting platform. Meanwhile, it's weighing up seven non-binding offers for all or parts of the business, although nothing's locked in yet, and is discussing changes to its financing facility with Northleaf. ASX laggards. Today's worst performing stocks (including small caps) intraday: | / | Description | Last | % | Volume | MktCap | | 1AD | Adalta Limited | 0.003 | -17% | 3,995,624 | $9,636,507 | | AAU | Antilles Gold Ltd | 0.006 | -21% | 775,559 | $26,432,057 | | AD1 | Adneo Limited | 0.015 | -21% | 45,000 | $7,910,422 | | ADN | Andromeda Metals Ltd | 0.005 | -17% | 2,064,086 | $30,851,042 | | APX | Appen Limited | 1.120 | -16% | 5,667,214 | $360,486,598 | | BNLDB | Blue Star Helium Ltd | 0.105 | -16% | 196,772 | $15,382,389 | | CYL | Catalyst Metals | 4.070 | -22% | 4,194,022 | $1,375,348,643 | | DAI | Decidr Ai Industries | 0.205 | -28% | 930,795 | $101,149,204 | | DTZ | Dotz Nano Ltd | 0.018 | -18% | 381,286 | $17,273,216 | | DXN | DXN Limited | 0.115 | -57% | 46,058,248 | $99,847,813 | | EDE | Eden Inv Ltd | 0.057 | -16% | 883,168 | $42,967,819 | | ELS | Elsight Ltd | 1.885 | -18% | 2,670,712 | $519,878,163 | | GNM | Great Northern | 0.020 | -17% | 61,761 | $11,852,123 | | HIQ | Hitiq Limited | 0.003 | -25% | 5,213,178 | $4,635,734 | | I88 | Infini Resources Ltd | 0.115 | -18% | 573,552 | $15,149,013 | | M2M | Mtmalcolmminesnl | 0.004 | -20% | 1,675,000 | $3,967,333 | | M2R | Miramar | 0.002 | -20% | 1,975 | $6,592,468 | | MGT | Magnetite Mines | 0.009 | -18% | 3,151,352 | $2,519,156 | | OSX | Osteopore Limited | 0.003 | -25% | 160,587 | $2,774,372 | | OVT | Ovanti Limited | 0.001 | -33% | 6,250 | $1,847,511 | | SEQ | Sequoia Fin Grp Ltd | 0.047 | -19% | 473,292 | $7,109,365 | | SP3 | Specturltd | 0.006 | -25% | 2,348,267 | $3,327,382 | | TOU | Tlou Energy Ltd | 0.001 | -67% | 15,296 | $3,895,753 | | TYX | Tyranna Res Ltd | 0.003 | -17% | 232 | $11,748,449 | | X2M | X2M Connect Limited | 0.003 | -25% | 97,464,178 | $10,378,192 | In case you missed it. Talonx Resources (ASX:TXR) has secured $775,000 in placement commitments to advance Kihabe copper exploration in Botswana and Viking gold drilling. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

PerthNow
Oct 30th, 2026
Aussie shares track strong weekly finish, Coles tumbles.

Aussie shares track strong weekly finish, Coles tumbles. Adrian BlackAAP 29 October 2026, 7:16pm Australia's share market is on track for its best weekly performance since July, shrugging off a Wall Street slump as local bank stocks continue their comeback. The S&P/ASX200 rose 94.3 points by midday, up 1.06 per cent, to 8986.4, as the broader All Ordinaries improved by 89.2 points, or 0.99 per cent, to 9101.8. The heavyweight financials sector provided much of the momentum, as investors sought safety in Australia's banks after US tech earnings raised questions about artificial intelligence's projected returns. "Wall Street turned decidedly sour as investors penalised tech heavyweights for aggressive spending and elusive pay-offs," Moomoo chief market strategist Tapas Strickland said. "Google parent Alphabet suffered its steepest single-day decline in company history, tumbling 12.6 per cent." CommBank was the best of the big four banks, up 1.6 per cent to $169 per share. There were signs of institutional buying across much of the market, with blue-chip names like Wesfarmers, Woolworths, and Transurban receiving healthy share price injections. Origin was another strong performer, but its more than two per cent push came after its revenue soared in the first quarter on the back of strong LNG prices. Coles was a notable exception, tumbling almost seven per cent top $21.85 after its $11.2 billion first-quarter sales disappointed investors. The energy sector climbed 0.9 per cent despite a continued retreat in oil prices after reports US officials were seeking talks with Iran. Again, bigger names in the segment were finding buyers, with Woodside, Santos, Yancoal and New Hope Corporation providing most of the support. Mining stocks were heavy, coming into a second session of losses after rebounding earlier in the week. BHP traded flat at $57.52, while Rio and Fortescue lost ground as copper prices reversed and iron ore futures lingered just below $US91 a barrel. Precious metals producers were also under pressure, as spot gold eased to $US4004 ($5699) an ounce. Consumer cyclicals have rebounded strongly with a 2.5 per cent advance, helping it recoup some of the previous four sessions' losses. Bitcoin has tumbled more than 5.5 per cent in the past two days to $US77,000 ($A109,605) after a suspected hack at major cryptocurrency exchange Binance. In company news, sleep device maker Resmed's revenue lifted six per cent in the September quarter to $US418 million ($595 million), beating out forecasts. Reece also posted strong results, with the plumbing goods supplier's shares jumping almost 10 per cent after first-quarter sales of $2.5 billion, up 4.3 per cent on the equivalent quarter. Star Entertainment shares are trading 3.5 per cent higher after the casino group came out of a trading halt, following reports its $260 million Federal Court fine for money laundering obligation breaches will be paid off in instalments. The Australian dollar is buying 70.26 US cents, down from 70.47 US cents on Thursday at 5pm.

The Motley Fool Australia
Oct 30th, 2026
Would I buy ResMed shares after today's results?

Would I buy ResMed shares after today's results? The company has reported solid revenue and earnings growth. Here's what I make of its performance and current valuation. Published October 30, 11:47 am AEDT ResMed Inc (ASX: RMD) shares are having a positive finish to the week. Shares in the sleep technology giant are up 2% to around $36.15 on Friday, following the release of the company's first-quarter results. But are the results good enough to make ResMed shares a buy at current levels? What did ResMed report? According to its ASX announcement, ResMed delivered a solid start to FY27, reporting a 6% increase in revenue to US$1.41 billion for the first quarter. On a core constant currency basis, revenue growth was slightly stronger at 7%. Demand for its sleep and breathing health products remained healthy, with global sleep device revenue increasing 9% and masks and other products growing 10%. I think these are encouraging numbers. There was also good news on profitability. The company's adjusted gross margin improved by 50 basis points to 62.5%, helped by ongoing productivity improvements. This contributed to a 14% increase in adjusted earnings per share (EPS), comfortably ahead of revenue growth. As for the outlook, management maintained its FY27 guidance. ResMed continues to expect reported revenue of US$5.75 billion to US$5.85 billion, with core constant currency revenue growth of 5% to 7%. Its adjusted earnings guidance was also left unchanged. I think ResMed's first-quarter performance provides a solid start towards achieving those targets. Would I buy ResMed shares? I am positive on ResMed's long-term prospects, and today's results have reinforced that view. The company has an excellent position in the global sleep health market, supported by its established brand, extensive product range, and continued investment in innovation. Importantly, there is still a substantial opportunity to grow. Millions of people around the world are living with undiagnosed or untreated obstructive sleep apnoea, and I expect awareness and access to treatment to improve over time. ResMed is well placed to benefit from this trend, especially as it continues expanding internationally and developing new products. I also like the company's focus on improving efficiency, which could allow earnings to grow faster than revenue over the coming years. And what about its valuation? Based on CommSec consensus forecasts at 30 October, ResMed shares are trading on a forward price-to-earnings (P/E) ratio of approximately 21.3 times FY27 earnings. That reduces to 19.4 times for FY28, then to 17.5 times for FY29. It is also possible that consensus EPS estimates could change for the better following the company's encouraging start to the year, lowering these multiples a touch. Of course, investors should keep in mind that this valuation assumes ResMed continues delivering earnings growth. Any slowdown or pressure on profitability could weigh on its share price. Nevertheless, I think the current multiples look reasonable for a business with ResMed's market position and long-term growth opportunities. Foolish takeaway. Today's results have given me another reason to feel confident about ResMed shares. The company continues to grow, its profitability is improving, and there is still a substantial global market for its products. At around $36.15, I think ResMed shares offer good value for long-term investors. In light of this, I would be happy to buy and give the company plenty of time to grow.

Business Insider
Oct 29th, 2026
Ozlo raises $22M Series B led by Modi Ventures as sleepbuds hit 260,000 customers

Sleep technology company Ozlo has raised $22 million in Series B funding led by Modi Ventures. The round includes previously issued convertible instruments, and existing investors such as LifeArc, Artis Ventures, and Resmed took part. The Boston-based maker of Ozlo Sleepbuds has passed 260,000 customers in under two years. It will use the money to grow globally, invest in hardware, software, and research, and move beyond earbuds into broader sleep and nighttime health. That includes regulatory work to submit a tinnitus product to the US Food and Drug Administration for review. Ozlo also partners with Dreem Health, a virtual sleep clinic, to connect users with sleep specialists. In July 2026, it launched Sleepbuds 2, with up to 14 hours of battery life.